Lexicon Pharmaceuticals Inc [LXRX] stock is trading at $1.7, down -3.41%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LXRX shares have gain 32.81% over the last week, with a monthly amount glided 39.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock has seen the most recent analyst activity on March 05, 2025, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $1 from $2. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 17, 2024, and set its price target to $10. On April 30, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $5 on the stock. Jefferies started tracking the stock assigning a Hold rating and suggested a price target of $3 on March 07, 2023. Piper Sandler initiated its recommendation with a Overweight and recommended $10 as its price target on August 12, 2022. JP Morgan upgraded its rating to Neutral for this stock on January 29, 2021, but kept the price target unchanged to $7. In a note dated January 29, 2021, Wedbush downgraded an Neutral rating on this stock and boosted its target price from $2 to $8.
Lexicon Pharmaceuticals Inc [LXRX] stock has fluctuated between $0.28 and $1.83 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] shares were valued at $1.7 at the most recent close of the market. An investor can expect a potential return of 252.94% based on the average LXRX price forecast.
Analyzing the LXRX fundamentals
Lexicon Pharmaceuticals Inc [NASDAQ:LXRX] reported sales of 70.86M for the trailing twelve months, which represents a growth of 710.40%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -0.94%, Pretax Profit Margin comes in at -0.97%, and Net Profit Margin reading is -0.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.53 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Lexicon Pharmaceuticals Inc’s Current Ratio is 5.64. As well, the Quick Ratio is 5.63, while the Cash Ratio is 2.29. Considering the valuation of this stock, the price to sales ratio is 8.72, the price to book ratio is 5.14.
